Skip to main content

Table 1 Baseline characteristics of all patients

From: Insulin resistance exhibits varied metabolic abnormalities in nonalcoholic fatty liver disease, chronic hepatitis B and the combination of the two: a cross-sectional study

  ALL HC CHB NAFLD CHB with NAFLD
(N = 2768) (N = 667) (N = 970) (N = 878) (N = 253)
Gender (male) 1901 (69%) 440 (66%) 651 (67%)
NSa
618 (70%)
NSab
192 (76%)
*ab, NSc
Age (year) 40.1 (10.9) 39.3 (9.2) 39.8 (11.7)
NSa
41.1 (12.0)
NSab
41.0 (10.2)
NSac, *b
BMI (kg/m2) 23.8 (3.9) 21.8 (2.4) 22.2 (3.1)
**a
26.5 (3.7)
**ab
26.0 (3.7)
**ab, *c
Waist–hip ratio 0.85 (0.07) 0.80 (0.06) 0.84 (0.07)
**a
0.89 (0.04)
**ab
0.89 (0.05)
**ab, NSc
SBP (mmHg) 124.2 (13.1) 116.2 (12.1) 124.8 (10.1)
**a
127.7 (14.7)
**ab
130.0 (10.8)
**ab, *c
DBP (mmHg) 79.8 (9.9) 72.1 (9.2) 82.3 (8.1)
**a
82.4 (9.9)
**a, *b
86.0 (11.1)
**ab
CHOL (mmol/L) 5.1 (1.0) 4.7 (0.6) 4.9 (1.1)
**a
5.5 (1.1)
**ab
5.2 (1.1)
**ab, *c
TG (mmol/L) 1.6 (1.7) 1.0 (0.5) 1.3 (0.8)
**a
2.5 (2.5)
**ab
1.7 (1.3)
**ab
HDL-C (mmol/L) 1.3 (0.4) 1.4 (0.2) 1.3 (0.4)
NSa
1.1 (0.3)
**ab
1.2 (0.4)
**ab, NSc
LDL-C (mmol/L) 3.1 (0.9) 2.9 (0.7) 3.1 (0.8)
**a
3.3 (0.9)
**ab
3.4 (0.9)
**ab, NSc
FBG (mmol/L) 5.0 (0.9) 4.8 (0.4) 4.8 (0.7)
NSa
5.4 (1.2)
**ab
5.3 (1.3)
**ab, *c
FINS (μU/mL) 8.7 (6.3) 6.2 (3.4) 7.3 (4.8)
*a
11.3 (7.4)
**ab
12.0 (7.9)
**ab, NSc
HOMA-IR 2.0 (1.8) 1.3 (0.8) 1.6 (1.3)
*a
2.7 (2.1)
**ab
2.9 (2.6)
**ab, NSc
UA (μmol/L) 358.2 (102.4) 309.1 (89.0) 339.0 (92.2)
**a
402.8 (102.2)
**ab
401.9 (93.2)
**ab, NSc
ALT (U/L) 45.9 (63.5) 20.1 (10.9) 55.1 (90.9)
**a
51.4 (44.4)
**ab
61.5 (64.5)
**ab,*c
AST (U/L) 37.1 (49.0) 24.4 (6.0) 44.2 (75.4)
**a
37.3 (26.2)
**a, *b
44.0 (43.1)
**a, *bc
ALB (g/L) 45.6 (3.2) 46.5 (0.2) 44.9 (4.1)
**a
45.97 (2.8)
**ab
45.2 (3.8)
**ac, *b
TB (μmol/L) 14.6 (5.3) 13.6 (0.2) 15.2 (6.8)
*a
14.46 (5.1)
**a, NSb
14.5 (6.2)
*a, NSbc
  1. HC: health control; NAFLD: nonalcoholic fatty liver disease; CHB: chronic hepatitis B; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; CHOL: total cholesterol; TG: triglycerides; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; UA: uric acid; ALB: albumin; TB: total bilirubin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; FBG: fasting blood glucose; FINS: serum insulin
  2. Data are n (%) and mean (Standard deviation). P values were for the ANOVA analysis across the groups, * P < 0.05, ** P < 0.001
  3. a—compared with HC group, b—compared with CHB group, c—compared with NAFLD group, NS— non significant